Back to top
more

BioNTech (BNTX)

(Real Time Quote from BATS)

$110.05 USD

110.05
193,577

+0.02 (0.02%)

Updated Aug 5, 2025 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

by Sweta Killa

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

Zacks Equity Research

BioNTech (BNTX) Soars: Stock Adds 5.2% in Session

by Zacks Equity Research

BioNTech (BNTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Pfizer (PFE) Progressing Well With its Coronavirus Program

by Zacks Equity Research

Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.

Zacks Equity Research

Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (BNTX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Kinjel Shah headshot

Pfizer, Regeneron Give Update on Coronavirus Drug Development

by Kinjel Shah

Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.

Zacks Equity Research

Company News for Mar 18, 2020

by Zacks Equity Research

Companies In The News Are: PFE, BNTX, REGN, DNKN. TMO.

Zacks Equity Research

Moderna Up as First Human Trial of Coronavirus Vaccine Begins

by Zacks Equity Research

Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.

Zacks Equity Research

Company News for Mar 17, 2020

by Zacks Equity Research

Companies In The News Are: BNTX, MRNA, UAL, AAL.

Zacks Equity Research

Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon

by Zacks Equity Research

A low-key week for the biotech sector with a few pipeline and regulatory updates.